KORU Medical Systems, Inc. (KRMD) is a Nasdaq-listed medical device company that designs and commercializes subcutaneous infusion systems used in large-volume drug delivery and contract manufacturing. Its current analyst coverage centers on four recently updated targets: Piper Sandler reiterated a Hold with a $5 target, Canaccord Genuity and Craig-Hallum both reiterated Buy ratings at $6, and B. Riley Securities reiterated a Buy at $8. The arithmetic mean of these four figures is $6.25, with a range of $5.00 to $8.00.
The dispersion is notable. The most cautious view (Piper Sandler) still sits about 55% above the current price, while the highest target implies roughly 148% upside. In a sign of tempered enthusiasm, Craig-Hallum trimmed its target from $7 to $6 in early August 2026 even while maintaining its Buy rating, whereas B. Riley raised its target to $8 in March. This mix of a reduced target at one firm and a raised target at another underscores that analysts are not in lockstep about the pace of the company's recovery.
At a recent price near $3.23, KRMD sits toward the lower end of its 52-week range of roughly $2.86 to $6.61, with a market capitalization near $149 million. Moving to $6.25 from $3.23 requires an advance of about 94%, which is a very large move for a small-cap name over any reasonable horizon. The path would likely depend on sustaining revenue momentum, converting that growth into consistent profitability, and rebuilding investor confidence after a decline of roughly 49% from the start of 2026.
Fundamentals show encouraging signs: trailing twelve-month revenue has grown more than 20% year over year to roughly $45 million, and the company has been narrowing losses toward breakeven, with recent quarters showing improved operating performance. However, the stock trades on negative EPS (earnings per share), meaning it cannot yet be valued on a conventional P/E (price-to-earnings) basis, which adds uncertainty to any price forecast.
Several factors underpin the bullish analyst price targets. Revenue has grown at a double-digit pace, driven by both domestic and international core product demand plus pharma-services activity. Gross margins remain healthy, and the company has been steadily reducing operating losses, suggesting an improving path toward profitability. Continued execution on this trajectory — alongside new drug-pump partnerships, regulatory clearances, or larger contract-manufacturing deals — could give analysts reason to hold or raise their targets.
Valuation also plays a role. The bullish firms argue that shares, trading near multi-year lows after a steep sell-off, may over-discount the company's growth prospects. If revenue growth persists and losses keep narrowing, a re-rating toward the higher end of the analyst range becomes a more plausible scenario.
The principal risk is that the recent stock decline reflects genuine skepticism rather than mispricing. The shares sit below both their 50-day and 200-day moving averages, signaling persistent selling pressure. As a small-cap with a limited product line concentrated in subcutaneous infusion technology, KORU Medical is exposed to customer concentration, reimbursement and regulatory changes, and competition from larger medical-device players.
Any slowdown in revenue growth, a guidance cut, or a return to wider operating losses could undercut the higher analyst targets. The gap between the $5 and $8 targets also shows that analysts themselves disagree on how quickly — or whether — the company can deliver sustained profitability.
Technically, the picture is challenging. The 52-week low near $2.86 stands as the key support level to hold, while the psychological $5.00 level and the prior highs near $6.60 represent major resistance zones on the way toward the $6.25 target. The stock trades below its long-term moving averages, and any durable recovery would first require reclaiming those averages before a sustained advance toward the analyst targets becomes credible.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary in their methodology and timing. Upcoming items most relevant to the target include the company's quarterly earnings releases and guidance, any changes to analyst ratings or targets, new product or partnership announcements, and developments in the broader medical-device and drug-delivery sector. Investors should also watch whether the company can string together consecutive quarters of revenue growth with shrinking losses.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap like KORU Medical Systems, such tools can help traders spot changing trends and monitor positions more efficiently than manual review alone. Traders can use these signals to discover new opportunities and stay alert to momentum shifts as they unfold.
Can KORU Medical Systems (KRMD) stock reach $6.25? The target, an arithmetic mean of four current analyst targets spanning $5 to $8, implies a very large gain of about 94% from recent levels near $3.23. The bull case rests on sustained double-digit revenue growth and a narrowing path to profitability, while the bear case centers on persistent technical weakness, negative earnings, and a small-cap's concentration risks. With analysts themselves split across a wide range, the question ultimately hinges on execution: whether the company can keep growing revenue and turn that growth into consistent profits. Investors should watch earnings, guidance, and analyst revisions rather than treating the $6.25 average as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KRMD has been loosely correlated with QDEL. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if KRMD jumps, then QDEL could also see price increases.
| Ticker / NAME | Correlation To KRMD | 1D Price Change % | ||
|---|---|---|---|---|
| KRMD | 100% | -2.17% | ||
| QDEL - KRMD | 40% Loosely correlated | -4.71% | ||
| A - KRMD | 40% Loosely correlated | -1.27% | ||
| CLPT - KRMD | 39% Loosely correlated | -4.36% | ||
| BIO - KRMD | 38% Loosely correlated | -0.47% | ||
| NVST - KRMD | 35% Loosely correlated | -0.50% | ||
More | ||||
| Ticker / NAME | Correlation To KRMD | 1D Price Change % |
|---|---|---|
| KRMD | 100% | -2.17% |
| Pharmaceuticals: Other industry (49 stocks) | 29% Poorly correlated | +1.90% |
| Pharmaceuticals industry (151 stocks) | 14% Poorly correlated | +0.95% |